Please click on a link below to view the relevant section
M.Baum
Conception after breast cancer: a word of comfort.
Int J Surg. 2008 Apr;6(2):96-7. Epub 2007 Feb 2
Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group, Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial.
Lancet Oncol. 2008 Jan;9(1):45-53.
Demicheli R, Retsky MW, Hrushesky WJ, Baum M.
Tumor dormancy and surgery-driven interruption of dormancy in breast cancer: learning from failures.
Nat Clin Pract Oncol. 2007 Dec;4(12):699-710.
Demicheli R, Retsky MW, Hrushesky WJ, Baum M.et al
Racial disparities in breast cancer outcome: insights into host-tumor interactions.
Cancer. 2007 Nov 1;110(9):1880-8.
A lifetime in breast cancer research. Baum M.
Eur J Cancer. 2007 Jul;43(10):1496-7
Demicheli R, Retsky MW, Hrushesky WJ, Baum M.Gukas ID, Jatoi I.
Racial disparities in breast cancer outcome: insights into host-tumor interactions.
Cancer. 2007 Sep 17; [Epub ahead of print]
The TARGIT trial: targeted intraoperative radiation therapy versus conventional postoperative whole-breast radiotherapy after breast-conserving surgery for the management of early-stage invasive breast cancer (a trial update).
Am J Surg. 2007Oct;194(4):507-10.
Complementary/Alternative therapies for the treatment of breast cancer. A systematic review of randomized clinical trials and a critique of current terminology.
Breast J. 2006 Nov-Dec;12(6):526-30. Review
Targeted intraoperative radiotherapy (TARGIT) yields very low recurrence rates when given as a boost.
Int J Radiat Oncol Biol Phys. 2006 Dec 1;66(5):1335-8. Epub 2006 Nov 2.
The role of complementary and alternative medicine in the management of early breast cancer: recommendations of the European Society of Mastology (EUSOMA).
Eur J Cancer. 2006 Aug;42(12):1711-4
Baum M, Ernst E, Lejeune S, Horneber M.
Role of complementary and alternative medicine in the care of patients with breast cancer: report of the European Society of Mastology (EUSOMA) Workshop, Florence, Italy, December 2004.
Eur J Cancer. 2006 Aug;42(12):1702-10
Tobias JS, Vaidya JS, Keshtgar M, Douek M, Metaxas M, Stacey C, Sainsbury R, D'Souza D, Baum M.
Breast-conserving surgery with intra-operative radiotherapy: the right approach for the 21st century?
Clin Oncol (R Coll Radiol). 2006 Apr;18(3):220-8. Review
Letrozole or tamoxifen in early breast cancer.
N Engl J Med. 2006 Apr 6;354(14):1528-30
Ramifications of screening for breast cancer: consent for screening.
BMJ. 2006 Mar 25;332(7543):728
Adjuvant goserelin in pre-menopausal patients with early breast cancer: Results from the ZIPP study.
Eur J Cancer. 2006 May;42(7):895-904. Epub 2006 Mar 20.
Dowsett M, Houghton J, Iden C, Salter J, Farndon J, A'Hern R, Sainsbury R, Baum M.
Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status.
Ann Oncol. 2006 May;17(5):818-26
Retsky MW, Hrushesky W, Baum M.
Sociodemographic determinants of cancer treatment health literacy.
Cancer. 2005 Dec 20
Dowsett M, Cuzick J, Wale C, Howell T, Houghton J, Baum M.
Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study.
J Clin Oncol. 2005 Oct 20;23(30):7512-7.
Adjuvant endocrine therapy in postmenopausal women with early breast cancer: where are we now?
Eur J Cancer. 2005 Aug;41(12):1667-77.
Breast cancer survival and the use of HRT.
Breast. 2005 Jun;14(3):178-80
TARGeted Intraoperative radiotherapy (TARGIT): an innovative approach to partial-breast irradiation.
Semin Radiat Oncol. 2005 Apr;15(2):84-91
Baum M, Demicheli R, Hrushesky W, Retsky M.
Does surgery unfavourably perturb the "natural history" of early breast cancer by accelerating the appearance of distant metastases?
Eur J Cancer. 2005 Mar;41(4):508-15.
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.
Lancet. 2005 Jan 1-7;365(9453):60-2.
Baum M. Breast cancer screening comes full circle.
J Natl Cancer Inst. 2004 Oct 20;96(20):1490-1
Baum M & Schipper H. Fast Facts Breast Cancer 3rd Edition, Health Press, London 2005
References 2004:
Baum M.
The endocrine management of postmenopausal women with early breast cancer. Breast Cancer. 2004;11(1):15-9.
Baum M Making Amends misses the point.
BMJ. 2004 Feb 14;328(7436):407.
Intraoperative radiotherapy for breast cancer.
Lancet Oncol. 2004 Mar;5(3):165-73.
Baum M.
Commentary: false premises, false promises and false positives--the case against mammographic screening for breast cancer.
Int J Epidemiol. 2004 Feb;33(1):66-7
Adjuvant use of anastrozole in breast cancer.
J Clin Oncol. 2004 Apr 15;22(8):1524-6
Tobias JS, Vaidya JS, Keshtgar M, D'Souza DP, Baum M.
Reducing radiotherapy dose in early breast cancer: the concept of conformal intraoperative brachytherapy.
Br J Radiol. 2004 Apr;77(916):279-84
Fennessy M, Bates T, MacRae K, Riley D, Houghton J, Baum M.
Late follow-up of a randomized trial of surgery plus tamoxifen versus tamoxifen alone in women aged over 70 years with operable breast cancer.
Br J Surg. 2004 Jun;91(6):699-704.
Gray LC, Vaidya JS, Baum M, Badwe RA, Mittra I, Siddiqui T, Wiarda D.
Functional Maps of Metastases from Breast Cancers: Proof of the Principle that Multidimensional Scaling Can Summarize Disease Progression.
World J Surg. 2004 Jun 8
Vaidya JS, Tobias J, Baum M, Keshtgar M, Houghton J, Wenz F, Corica T, Joseph D.
Intraoperative radiotherapy: the debate continues.
Lancet Oncol. 2004 Jun;5(6):339-40
Baum M.
Does the act of surgery provoke activation of "latent" metastases in early breast cancer?
Breast Cancer Res. 2004;6(4):160-1.
Baum M.
The use and abuse of human tissue: an analysis of the ethical issues raised by the proposed Human Tissue Act.
Med Leg J. 2004;72(Pt 2):67-9
Baum M.
Current Status of Aromatase Inhibitors in the Management of Breast Cancer and Critique of the NCIC MA-17 Trial Cancer Control. 2004 Jul-Aug;11(4):217-21.
Jassem J, Buchanan M, Janicke F, Baum M, Cataliotti L, Kyriakides S, Piccart M, Rutgers EJ, Costa A.
The Hamburg statement: the partnership driving the European agenda on breast cancer. Eur J Cancer. 2004 Aug;40(12):1810-1
Baum M & Henderson C. ed. Classic Papers in Breast Disease , Martin Dunitz, London New York, 2004
Key References prior to 2004
The Statement of Barcelona: The future of Breast Cancer Research in Danger.
Baum M, Buchanan M, Baselga J, Cataliotti L, Jassem J, Piccart M
European Journal of Cancer, 2002, 38;2210-2213
The ATAC (Arimidex,Tamoxifen Alone or in Combination) Trialist group.
Anastrozole alone or in combination for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.
The Lancet 2002; 359: 2131-2139
Baum M, Chaplain M, Anderson A, Douek M, Vaidya JS. Does breast cancer exist in a state of chaos? Eur J Cancer 1999; 35: 886–91.
Schipper H, Turley EA, Baum M. A new biological framework for cancer research. Lancet 1996; 348: 1149–51.
Baum M, Benson JR Current and future roles of adjuvant endocrine therapy in management of early carcinoma of the breast. In Senn HJ, Gelber RD, Goldhirsch A, Thurlimann B, eds. Recent Results in CancerResearch—Adjuvant Therapy of Breast Cancer. Heidelberg: Springer, 1996:215–226.
Controlled trial of tamoxifen as adjuvant agent in management of Early Breast Cancer. Interim analysis at four years by the Nolvadex Adjuvant Trial Orginisation. Baum M, Brinkley DM, Dossett JA, et al
The Lancet Feb. 5th ,1983; 257- 261